Glycopyrollate

# Glycopyrollate ## Overview - **Classification**: Anticholinergic, muscarinic antagonist. - **Mechanism**: Selectively blocks muscarinic acetylcholine receptors, reducing glandular secretions (salivary, bronchial, gastric) and GI smooth muscle spasms. ## Primary Indications 1. **Preoperative use** - Reduce salivary, tracheobronchial, and pharyngeal secretions. 2. **Protection against bradycardia** - During anesthesia or as an adjunct for neuromuscular blockade reversal. 3. **Chronic severe drooling** - In patients 3-16 years old (oral solution). 4. **Peptic Ulcer Disease** - Adjunctive therapy (oral tablets). 5. **Hyperhidrosis** - Excessive underarm sweating (topical wipes). ## Adult Dosing ### Standard Dosing **Preoperative (Reduction of Secretions/Bradycardia Prophylaxis)** - **Dose**: **0.004-0.008 mg/kg** (typically **0.1-0.2 mg**) - **Frequency**: Single dose - **Route**: IM or IV - **Maximum dose**: **0.4 mg** per single dose **Adjunct in Neuromuscular Blockade Reversal** - **Dose**: **0.2 mg** for every **1 mg neostigmine** or **0.5 mg** for every **2.5 mg pyridostigmine** - **Frequency**: Single dose concurrently with cholinesterase inhibitor - **Route**: IV **Chronic Severe Drooling (Oral Solution/Tablets)** - **Dose**: Initial **1-2 mg** - **Frequency**: BID or TID, titrated based on response - **Route**: Oral - **Maximum dose**: **8 mg/day** **Adjunctive Therapy for Peptic Ulcer (Oral Tablets)** - **Dose**: **1-2 mg** - **Frequency**: TID or 2 mg BID-TID - **Route**: Oral - **Maximum dose**: **8 mg/day** ### Dose Adjustments - **Renal Impairment**: Reduce dose in **CrCl < 30 mL/min**. Avoid in severe renal impairment for peptic ulcer. - **Hepatic Impairment**: No specific adjustments; use with caution. - **Elderly Patients**: Start with lower doses due to increased sensitivity to anticholinergic effects. Monitor for cognitive changes. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **0.004 mg/kg/dose** (IV/IM) - **Frequency**: Single dose - **Maximum**: **0.1 mg/dose** - **Special Notes**: Use with extreme caution due to limited data and potential for serious adverse effects. ### Infants (1-12 months) - **Preoperative (IV/IM)**: **0.004-0.008 mg/kg/dose** - **Frequency**: Single dose - **Maximum**: **0.1 mg/dose** - **Drooling (Oral Solution)**: Initial **0.02 mg/kg/dose** - **Frequency**: BID or TID; titrate to response. - **Maximum**: **0.05 mg/kg/dose** (single) or **0.1 mg/kg/day** (daily), not to exceed **3 mg/day**. ### Children (1-12 years) - **Preoperative (IV/IM)**: **0.004-0.008 mg/kg/dose** - **Frequency**: Single dose - **Maximum**: **0.2 mg/dose** - **Drooling (Oral Solution)**: Initial **0.02 mg/kg/dose** - **Frequency**: BID or TID; titrate to response. - **Maximum**: **0.05 mg/kg/dose** (single) or **0.1 mg/kg/day** (daily), not to exceed **3 mg/day**. ### Adolescents (13-18 years) - **Dose**: Generally follow adult dosing guidelines. - **Maximum**: Adult maximum doses. ## Safety Information ### Contraindications - **Absolute**: Angle-closure glaucoma, myasthenia gravis (unless used to reverse NMB). - **Absolute**: Obstructive uropathy, paralytic ileus, toxic megacolon, severe ulcerative colitis. - **Absolute**: Acute hemorrhage with cardiovascular instability. - **Relative**: Severe renal impairment (for chronic use). ### Common Adverse Effects - **Very Common (>10%)**: Dry mouth, blurred vision, urinary retention, constipation. - **Common (1-10%)**: Dizziness, headache, nausea, vomiting, nervousness, tachycardia. - **Serious but Rare**: Anaphylaxis, severe allergic reaction, heat stroke. ### Key Drug Interactions - **Anticholinergics (e.g., TCAs, antihistamines)**: Increased risk of additive anticholinergic side effects (dry mouth, urinary retention). - **Potassium chloride oral solids**: Increased risk of GI lesions due to slowed GI motility. Avoid concurrent use. - **Drugs metabolized by CYP450**: Glycopyrrolate is minimally metabolized, low risk of significant CYP interactions. ## Monitoring & Follow-up - **Before Treatment**: Assess for contraindications (e.g., glaucoma, urinary retention history). - **During Treatment**: Monitor for urinary retention, constipation, dry mouth, blurred vision, heart rate. - **Clinical Signs**: Watch for decreased sweating and signs of heat intolerance, especially in warm environments. ## Clinical Pearls - 💡 **Timing**: For oral forms, administer **1 hour before or 2 hours after meals** for optimal absorption. - 💡 **Heat Intolerance**: Warn patients that decreased sweating can lead to **hyperthermia**, especially during exercise or in hot weather. - 💡 **Oral Solution**: Useful for patients with dysphagia or those needing precise dose titration (especially in pediatrics). - 💡 **Vision**: Advise patients about potential **blurred vision** and caution regarding driving or operating machinery. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.